Opdivo vs Farxiga
Side-by-side drug price comparison from Medicare Part D data
Verdict
Farxiga costs 98% less per claim than Opdivo ($266.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Farxiga at $3.0B.
| Metric | Opdivo | Farxiga |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $15,821 | $266* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.1B | $3.0B |
| Total Claims | 324,000 | 11,240,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 15.8%* | 31.5% |
| Generic Available | Yes | Yes |
| Condition | Cancer | Diabetes |
| Total Beneficiaries | 66,000 | 1,340,000 |
Farxiga costs 98% less per claim than Opdivo ($266.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Farxiga at $3.0B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Opdivo and Farxiga. What follows is the interpretation — which specific axes carry the most weight for Opdivo versus Farxiga, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.